- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00199069
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)
March 15, 2023 updated by: Nicola Goekbuget, Goethe University
Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93)
The study evaluates the efficacy and tolerability of a risk- and subtype-adapted chemotherapy over one year, followed by randomized either intensified or conventional maintenance therapy.
It includes a distinct protocol for the subgroup 'mature B-ALL',
Study Overview
Status
Completed
Conditions
Intervention / Treatment
- Drug: Methotrexate
- Drug: Cyclophosphamide
- Drug: Vincristine
- Drug: Mitoxantrone
- Drug: Cytarabine
- Drug: Ifosfamide
- Drug: Dexamethasone / Prednisolone
- Drug: Asparaginase
- Drug: VM26
- Drug: 6-Mercaptopurine
- Procedure: Stem Cell Transplantation
- Drug: Daunorubicin, Adriamycin
- Drug: 6-Thioguanine
- Procedure: CNS Irradiation
- Procedure: Mediastinal Irradiation
Study Type
Interventional
Enrollment
720
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Frankfurt, Germany
- University Hospital, Medical Dept. II
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years to 65 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Acute Lymphocytic Leukemia
- Age 15 - 65 years
Exclusion Criteria:
- Serious secondary diseases which may compromise intensified chemotherapeutical treatment
- Serious psychiatric diseases, which may compromise compliance with therapy
- HIV-1 or HIV-2 Infection
- Pretreatment > 2 weeks or chemotherapy other than Vincristine and Steroids
- Patients without central diagnosis who cannot be allocated to a risk group
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
remission rate, disease free survival, overall survival
|
Secondary Outcome Measures
Outcome Measure |
---|
death in induction, toxicity, time and dose compliance
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Dieter Hoelzer, MD, PhD, University of Frankfurt, Medical Department II
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 1993
Primary Completion (Actual)
January 1, 1999
Study Completion (Actual)
May 1, 2001
Study Registration Dates
First Submitted
September 12, 2005
First Submitted That Met QC Criteria
September 12, 2005
First Posted (Estimate)
September 20, 2005
Study Record Updates
Last Update Posted (Actual)
March 17, 2023
Last Update Submitted That Met QC Criteria
March 15, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiviral Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Dermatologic Agents
- Antibiotics, Antineoplastic
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Dexamethasone
- Prednisolone
- Cyclophosphamide
- Ifosfamide
- Doxorubicin
- Cytarabine
- Methotrexate
- Vincristine
- Daunorubicin
- Asparaginase
- Mitoxantrone
- Mercaptopurine
- Thioguanine
Other Study ID Numbers
- GMALL09
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adult Acute Lymphocytic Leukemia
-
National Cancer Institute (NCI)CompletedRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditionsUnited States
-
Eastern Cooperative Oncology GroupCompletedAdult Patients (Over 55) With Acute Non-Lymphocytic Leukemia
-
Genzyme, a Sanofi CompanyCompletedSolid Tumors | Leukemia, Myelocytic, Acute, Pediatric | Leukemia, Lymphocytic, Acute, Pediatric | Leukemia, Lymphocytic, Acute, Adult | Leukemia, Myelocytic, Acute, Adult | Myelodysplastic Syndromes, AdultUnited States
-
First Affiliated Hospital of Wenzhou Medical UniversitySecond Affiliated Hospital of Nanchang University; Hrain Biotechnology Co.,...UnknownHematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | B-cell Adult Acute Lymphoblastic LeukemiaChina
-
National Cancer Institute (NCI)CompletedChronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia... and other conditionsUnited States
-
Goethe UniversityCompletedAdult Acute Lymphocytic LeukemiaGermany
-
Goethe UniversityCompletedAdult Acute Lymphocytic LeukemiaGermany
-
Goethe UniversityCompletedAdult Acute Lymphocytic LeukemiaGermany
-
Stanford UniversityCelgene CorporationTerminatedLeukemia | Relapsed Adult Acute Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Secondary Acute Myeloid Leukemia and other conditionsUnited States
Clinical Trials on Methotrexate
-
University Hospital, MontpellierPfizer; Hôpital CochinCompletedRheumatoid ArthritisFrance, Monaco
-
Nicolaus Copernicus UniversityCompleted
-
Amneal Pharmaceuticals, LLCAccutest Research Laboratories (I) Pvt. Ltd.Unknown
-
Hee Young JuNot yet recruitingLymphoblastic Leukemia in Children
-
PfizerCompletedRheumatoid ArthritisUnited States, Mexico, Argentina, Chile, Croatia, Czech Republic, Hungary, Poland, Puerto Rico
-
PfizerCompletedRhematoid ArthritisSpain, United Kingdom, United States, Korea, Republic of, Poland, Israel, Australia, Taiwan, Thailand, South Africa, Bulgaria, Estonia, Latvia, Philippines, Canada, Romania, Russian Federation, Turkey, Mexico, Bosnia and Herzegovina and more
-
Cairo UniversityCompleted
-
Chugai Pharma TaiwanCompletedRheumatoid Arthritis (RA)Taiwan
-
CHA UniversityCompleted
-
Mitsubishi Tanabe Pharma CorporationCompleted